STOCK TITAN
  1. Home
  2. News
  3. BNGO

Bionano Genomics Inc - BNGO STOCK NEWS

Welcome to our dedicated news page for Bionano Genomics (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bionano Genomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bionano Genomics's position in the market.

News
Bionano Announces Publication Demonstrating Utility of OGM to Assess Genome Integrity of CRISPR-Edited Cells as Part of Gene Therapy Development
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced a study demonstrating the use of optical genome mapping (OGM) to identify structural variations introduced by CRISPR-Cas9 gene editing of CD4+ T-cells, revealing the potential limitations of such edited cells for therapeutic use. The study found that while ddPCR assays are suitable to characterize certain expected mutations, they may miss large SVs. OGM outperformed karyotyping's resolution and sensitivity, revealing unexpected gene editing events and off-target structural variations. The study highlights the importance of comprehensive genome analysis in developing gene therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
none
-
News
Bionano Announces Presentation of OGM Utility Across Key Research Applications at the Association for Molecular Pathology Annual Meeting
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced its participation in the Association for Molecular Pathology (AMP) 2023 Annual Meeting and Expo. The company will present a broad range of content covering the utility of optical genome mapping (OGM) for cell and gene therapy and cancer research, including scientific workshops and poster presentations. The sessions will feature leading medical professionals presenting data on the role of structural variants in central nervous system (CNS) tumor analysis and hematological malignancy research conducted using OGM. The company will also showcase innovation in OGM workflow and product developments. In addition, 19 scientific posters will illustrate the application of OGM in research areas including hematological malignancies, solid tumor, constitutional disorders, and cell and gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
none
-
News
Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) reported Q3 2023 revenue of $9.3 million, a 29% increase over Q3 2022. They also announced the installation of 301 Saphyr® systems and the sale of 6,176 nanochannel array flowcells. Additionally, they completed an $80.0 million registered offering and private placement of senior secured convertible notes due 2025 and warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
earnings
News
Thompson and Thompson Genetics and Genomics in Medicine Includes OGM in Latest Edition, Notes Workflow’s Performance and Ability to Detect More SVs than LRS at Lower Cost
Rhea-AI Summary
Bionano Genomics announced that optical genome mapping (OGM) was included in the latest edition of Thompson and Thompson Genetics and Genomics in Medicine. OGM is described as a powerful tool for genome analysis, capable of detecting and validating structural variants (SVs) that sequencing techniques may miss. The authors of the book also note that OGM can be less expensive and more precise than long-read sequencing (LRS) in resolving complex SVs. This inclusion is a significant milestone for OGM and highlights its potential in clinical research investigations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.03%
Tags
none
-
News
Bionano to Present at the 2023 Stifel Healthcare Conference
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its CEO, Erik Holmlin, will present at the 2023 Stifel Healthcare Conference on November 15. The presentation will be available through a webcast and a recording will be accessible on the company's website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.03%
Tags
conferences
-
News
Bionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) will host a conference call and webcast on November 8, 2023, at 4:30 p.m. ET to report financial results for Q3 2023 and highlight recent corporate progress. Participants can access the live webcast on the Investors page of the Bionano website. A replay will be available on the company's investor relations website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
conferences earnings
News
Bionano Announces Presentation of OGM Utility Across Key Applications at the American Society of Human Genetics (ASHG) Annual Meeting
Rhea-AI Summary
Bionano Genomics will participate in the ASHG Annual Meeting 2023, presenting on the utility of optical genome mapping (OGM) in genetic disorder research. The conference will feature scientific presentations, poster sessions, and a sponsored session highlighting the latest research findings using OGM. Bionano's CEO, Erik Holmlin, expressed excitement about the variety and scale of the studies being presented, emphasizing the impact of OGM on genetic research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
News
Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan
Rhea-AI Summary
Bionano Genomics announces financing of $80 million, preliminary Q3 revenue of $9.1-9.3 million, and growth in installed base of Saphyr systems and nanochannel array flowcells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.85%
Tags
earnings
-
News
Bionano Announces Pricing of $80.0 Million Registered Offering and Concurrent Private Placement of Senior Secured Convertible Notes and Warrants
Rhea-AI Summary
Bionano Genomics announces pricing of convertible notes and warrants offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.85%
Tags
none
News
Benchmarking Study Shows Streamlined Structural Variant Detection and High Concordance for OGM Compared to Chromosomal Microarray Analysis, the Global Standard in Genetic Disease Analysis
Rhea-AI Summary
Bionano Genomics publishes benchmarking study comparing optical genome mapping (OGM) to chromosomal microarray analysis (CMA) for molecular analysis of genetic disorders. OGM shows 100% concordance with CMA for pathogenic variants, 98% concordance for clinically significant structural variants. OGM provides higher resolution and eliminates the need for reflex testing with FISH and KT. Positive potential for cost-effective workflow and simple interpretation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
Stock BNGO logo
Bionano Genomics Inc

Nasdaq:BNGO

BNGO Rankings

#4758 Ranked by Market Cap
#5501 Ranked by Stock Gains
N/A Ranked by Dividends

BNGO Stock Data

52.38M
54.49M
0.5%
11.91%
9.64%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
US
San Diego

About BNGO

at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o